Notice2024-04251
Government Owned Inventions Available for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 1, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 42 (Friday, March 1, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 42 (Friday, March 1, 2024)]
[Notices]
[Pages 15210-15211]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-04251]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions Available for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing
opportunity should be directed to: Andrew Burke Ph.D., Technology
Transfer Manager, NCI, Technology Transfer Center, email:
<a href="/cdn-cgi/l/email-protection#c8aabdbaa3ada9ba88a5a9a1a4e6a6a1a0e6afa7be"><span class="__cf_email__" data-cfemail="680a1d1a030d091a280509010446060100460f071e">[email protected]</span></a> or phone: (240) 276-5484.
SUPPLEMENTARY INFORMATION:
NIH Reference Number: E-251-2023-0.
Title: T Cell Receptors Targeting EGFR L858R mutation on HLA-
A*11:01 \+\ Tumors.
Tumor-specific mutated proteins can create neoepitopes, mutation-
derived antigens that distinguish tumor cells from healthy cells, which
are attractive targets for adoptive cell therapies. However, the
process of precisely identifying the neoepitopes to target is complex
and challenging. One method to identify such neoepitopes is Mass
Spectrometry (MS) when used in conjunction with elution of peptides
bound to a specific Human Leukocyte Antigen (HLA) allele. Using MS in
this
[[Page 15211]]
context can demonstrate which oncogene derived neoepitopes are
presented by common HLA alleles, and can provide the data necessary to
rapidly develop TCRs against the desired antigens.
Using the MS approach, inventors at the National Cancer Institute
(NCI) have identified neoepitopes derived from a mutated isoform of
Epithelial Growth Factor Receptor (EGFR) presented by HLA A*11:01
across multiple biological replicates. From this MS data, the inventors
were able to successfully isolate murine TCRs that specifically
recognize HLA A*11:01 restricted neoepitopes targeting EGFR L858R.
According to various cancer genome databases, EGFR L858R is highly
prevalent in lung adenocarcinoma, non-small cell lung carcinoma, and
non-squamous non-small cell lung carcinoma, making this driver mutation
an excellent target to develop off-the-shelf cellular therapies. The
clinical potential of these TCRs has not been explored.
Therapeutic Area(s): Cancer.
Research uses include: TCRs may be used as positive controls to
identify HLA-A*11:01 EGFR L858R reactive T cells from different sources
such as patients or animal models; TCRs recognize the common EGFR L858R
driver mutation in the context of HLA-A*11:01; EGFR; the prevalence of
EGFR L858R substitutions, relative to the overall EGFR mutation
population, ranges from 27.7% to 41.1% in non-small cell lung cancer
patients; HLA-A*11:01 allele frequency is particularly high (up to 60%)
in Asian and Oceanian populations. This research has validated the
effectiveness of using mass spectrometry to detect amino acid sequences
on specific HLA complexes.
Achieving expeditious commercialization of federally funded
research and development is consistent with the goals of the Bayh-Dole
Act, codified as 35 U.S.C. 200-212 and 37 CFR 404.4.
Development Stage: Research Tool.
Dated: February 26, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2024-04251 Filed 2-29-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 1, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.